A long-lasting pain condition associated with bortezomib treatment was indeed correlated to the presence of anxiety and depression in mice, and these behavioral changes were accompanied by increased levels of PK2 and PKR2 in the hippocampus and by a general neuroinflammatory condition in the hippocampus, prefrontal cortex, and hypothalamus. Here, PROK2 is linked to depressive symptom measurement.